CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2004-07-13): GlaxoSmithKline vaccine information wrong - US FDA

Regulatory

GlaxoSmithKline vaccine information wrong - US FDA

Last Updated: 2004-07-13 14:42:37 -0400 (Reuters Health)

WASHINGTON (Reuters) - Product materials for several GlaxoSmithKline Plc hepatitis vaccines contain false information about flu vaccines that could lead to public health problems, U.S. regulators said in a letter released on Tuesday.

Hepatitis vaccines Havrix, Twinrix and Engerix-B all included the company's version of general U.S. government vaccine guidelines but listed incorrect flu vaccine recommendations, the U.S. Food and Drug Administration wrote.

Glaxo's chart creates "a serious public health concern because it could lead to incorrect administration" of the live attenuated influenza vaccine to pregnant women with medical problems and very young children - for whom the drug has not been shown to be safe, the letter said.

The U.S. Centers for Disease Control and Prevention recommends flu vaccines for healthy people aged 5 to 49. The GlaxoSmithKline chart recommended the vaccine for children 6 months to 5 years old and for adults up to age 50, according to the FDA.

The wrong information was a particular concern because it "was distributed during the height of the flu season," the agency also said.

Glaxo spokeswoman Amanda Foley said the British drugmaker thought the information "was in compliance with FDA policies. Any omissions and statements the FDA objected to were not intentional."

The materials were distributed in late 2003 until early this year but have been discontinued, Foley said, adding that corrected information would be sent out.

Foley also said the company was reviewing all of its vaccine promotional materials to make sure they were FDA compliant.

The letter, which was dated July 6, was posted on Tuesday on the FDA Web site at www.fda.gov.

Materials for the hepatitis vaccines also failed to list critical safety warnings, including adverse reactions and medical conditions that should prevent some patients from getting the vaccine, the FDA said.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.